
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
SMYD2 CRISPR/Cas9 KO Plasmid (h) | sc-403129 | 20 µg | $397.00 | |||
SMYD2 HDR Plasmid (h) | sc-403129-HDR | 20 µg | $445.00 |
SMYD2 encodes a SET and MYND domain–containing lysine methyltransferase that modifies histone and non-histone substrates to regulate chromatin state, transcription, and cell-cycle control. In human cells, SMYD2-mediated methylation has been linked to modulation of DNA damage responses, apoptosis, and differentiation programs through its effects on chromatin-associated signaling and protein stability. By shaping epigenetic and proteomic outputs, SMYD2 influences pathways that govern proliferation and stress adaptation. Dysregulated SMYD2 activity and expression patterns are frequently studied in the context of oncogenic transcriptional programs and altered cellular growth phenotypes.
SMYD2 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the SMYD2 gene in human cell lines. Each plasmid in the pool co-expresses a unique sgRNA, targeting a distinct site within the SMYD2 locus, alongside the Streptococcus pyogenes Cas9 nuclease, and encodes GFP to enable fluorescent identification and enrichment of successfully transfected cells. This multi-guide strategy increases the likelihood of inducing frameshifts or deletions that produce a functional knockout, offering a more robust alternative to single-guide approaches. DSBs induced at multiple sites are resolved through non-homologous end joining (NHEJ) or, when used with the included HDR donor template, homology-directed repair (HDR) at a defined target site within the locus.
When used in conjunction with the RFP-expressing HDR donor, GFP and RFP fluorescence can be used together to distinguish transfected from edited cell populations, streamlining flow cytometry-based sorting and clone selection workflows.
For applications requiring confirmed, selectable knockout clones, SMYD2 HDR Plasmid (h) includes an HDR donor construct containing a puromycin resistance cassette (PuroR) and a red fluorescent protein (RFP) reporter, flanked by homology arms specific to a defined SMYD2 target site.
When co-transfected with SMYD2 CRISPR/Cas9 KO Plasmid (h):
The HDR donor construct features loxP sites flanking the PuroR-RFP selection cassette to allow clean marker removal following clone confirmation. Transient expression of Cre recombinase via the included Cre Vector: sc-418923 excises the cassette, leaving a minimal residual loxP site within the SMYD2 locus and eliminating potential confounding effects on downstream assays.
This two-step approach:
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.